Skip to main navigation
Skip to search
Skip to main content
Houston Methodist Scholars Home
Home
Experts
Research units
Cores
Projects
Research output
Prizes
Search by expertise, name or affiliation
View Scopus Profile
David S. Baskin, MD, FAANS, FACS
Kenneth R. Peak Presidential Distinguished Chair & Program Director, Neurosurgery Residency
,
Department of Neurosurgery
Professor of Neurosurgery
,
Academic Institute
Full Member
,
Research Institute
Kenneth R. Peak Brain & Pituitary Treatment Center
Neurological Institute
Houston Methodist Hospital
Houston Methodist
Weill Cornell Medical College
h-index
9293
Citations
38
h-index
Calculated based on number of publications stored in Pure and citations from Scopus
1979 …
2024
Research activity per year
Overview
Fingerprint
Network
Projects
(8)
Research output
(186)
Prizes
(1)
Similar Profiles
(6)
Research output
Research output per year
1979
1982
1986
1987
2013
2015
2016
2017
2021
2022
2024
129
Article
23
Chapter
11
Comment/debate
11
Letter
12
More
7
Review article
3
Patent
2
Conference contribution
Research output per year
Research output per year
3 results
Publication Year, Title
(descending)
Publication Year, Title
(ascending)
Title
Type
Filter
Patent
Search results
2022
METHOD AND APPARATUS FOR ONCOMAGNETIC TREATMENT
Helekar, S. A.
,
Baskin, D. S.
,
Sharpe, M. A.
&
Pichumani, K.
,
Jun 23 2022
, IPC No. A61N 2/ 12 A I, Patent No. US2022193436, Priority date
Dec 31 2021
, Priority No. US202117567101
Research output
:
Patent
neoplasms
100%
magnetic fields
77%
cell death
60%
apoptosis
60%
neoplasm cells
59%
2021
METHOD AND APPARATUS FOR ONCOMAGNETIC TREATMENT
Helekar, S. A.
,
Baskin, D. S.
,
Sharpe, M. A.
&
Pichumani, K.
,
Sep 22 2021
, IPC No. A61N 2/ 12 A I, Patent No. EP3880299, Priority date
Nov 13 2019
, Priority No. WO2019US61131
Research output
:
Patent
2013
COMPOUND COMPRISING A MAO TARGETING/SEEKER MOIETY FOR TREATING HUMAN GLIOMAS
Baskin, David, S.
&
Sharpe, Martyn, A.
,
Oct 10 2013
, IPC No. A61K 31/ 4375 A I, Patent No. CA2887928, Priority date
Oct 31 2012
, Priority No. WO2012US62850
Research output
:
Patent
Monoamine
100%
Antineoplastic Agent
76%